Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review

Martos-Fernández, Míriam; Sáez‐Barba, Manel; López‐López, José; Estrugo‐Devesa, Albert; Balibrea, José María; Bescós‐Atín, Coro

doi:10.1016/j.oooo.2018.02.004

Cited by 54 publications

(100 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the questioning of the effectiveness of hyperbaric oxygen therapy by Annane and prolonged antibiotic therapy by Madrid challenged the well‐established conservative approach to mandibular ORN. Currently, only the PENTOCLO protocol associated with conservative surgery (curettage or sequestrectomy) seems to have an efficacy higher than 60%, despite the absence of comparative studies with control groups and the low level of evidence from the various studies . For this purpose, it is also essential to define the limits of conservative management and shorten the time delay for effective management.…”

Section: Discussionmentioning

confidence: 99%

Role of “revascularisation surgery” in the management of mandibular osteoradionecrotic lesions: A report of 21 years of experience

Bettoni

Olivetto

Duisit

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Role of “revascularisation surgery” in the management of mandibular osteoradionecrotic lesions: A report of 21 years of experience

Bettoni

Olivetto

Duisit

et al. 2019

Clinical Otolaryngology

View full text Add to dashboard Cite

“…86 The combination of pentoxifylline and tocopherol has been used previously in the management of osteoradionecrosis, with significant improvement in symptomatology. 87 Pentoxifylline is a nonselective phosphodiesterase inhibitor that displays good therapeutic results against osteoradionecrosis of the jaws and MRONJ. [88][89][90][91] Tocopherol is a powerful scavenger of oxygen free radicals, which can reduce the damage caused by free radicals and necrosis.…”

Section: Therapy For Mronjmentioning

confidence: 99%

Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw

Sun

Liu

et al. 2020

Int J Oral Sci

View full text Add to dashboard Cite

Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of bone-modifying agents and inhibits angiogenesis agents. Although the pathogenesis of MRONJ is not entirely clear, multiple factors may be involved in specific microenvironments. The TGF-β1 signalling pathway may have a key role in the development of MRONJ. According to the clinical stage, multiple variables should be considered when selecting the most appropriate treatment. Therefore, the prevention and management of treatment of MRONJ should be conducted in patient-centred multidisciplinary team collaborative networks with oncologists, dentists and dental specialists. This would comprise a closed responsibility treatment loop with all benefits directed to the patient. Thus, in the present review, we aimed to summarise the pathogenesis, risk factors, imaging features, clinical staging, therapeutic methods, prevention and treatment strategies associated with MRONJ, which may provide a reference that can inform preventive strategies and improve the quality of life for patients in the future.

show abstract

“…Likewise, it has been proposed that previously noted injury-mitigating effects of pentoxifylline and dexamethasone treatments are the result of these drugs to regulate immune cell transit into radiation-damaged tissues. The combination of pentoxifylline and α-tocopherol has been demonstrated to be successful as well [114][115][116].…”

Section: Promising New Preventive/mitigative Agents Currently Under Pmentioning

confidence: 99%

“…As stated previously, radiation-induced fibrosis is a common long-term side effect of radiation damage within tissues and organ systems, including the reproductive system. There has been some experimental success in reversing induced fibrosis: treatments with agents such as copper/zinc SOD, MnSOD, or a combination of pentoxifylline and α-tocopherol [114][115][116], have shown positive results.…”

Section: Promising New Preventive/mitigative Agents Currently Under Pmentioning

confidence: 99%

Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems

Singh

Seed²

2020

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: There is a limited array of currently available medicinals that are useful for either the prevention, mitigation or treatment of bodily injuries arising from ionizing radiation exposure. Area covered: In this brief article, the authors review those pharmacologic agents that either are currently being used to counter the injurious effects of radiation exposure, or those that show promise and are currently under development. Expert opinion: Although significant, but limited progress has been made in the development and fielding of safe and effective pharmacotherapeutics for select types of acute radiation-associated injuries, additional effort is needed to broaden the scope of drug development so that overall health risks associated with both short-and long-term injuries in various organ systems can be reduced and effectively managed. There are several promising radiation countermeasures that may gain regulatory approval from the government in the near future for use in clinical settings and in the aftermath of nuclear/radiological exposure contingencies. ARTICLE HISTORY

show abstract

Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review

Cited by 54 publications

References 50 publications

Role of “revascularisation surgery” in the management of mandibular osteoradionecrotic lesions: A report of 21 years of experience

Role of “revascularisation surgery” in the management of mandibular osteoradionecrotic lesions: A report of 21 years of experience

Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw

Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems

Contact Info

Product

Resources

About